Aureus Pharma licenses AurWEB to Origenis
06.September 2006
Aureus Pharma licenses AurWEB to Origenis
Paris, FRANCE, September 2006 - Aureus Pharma a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces that Origenis, a Swiss-German based company who offers creative services in drug design, synthesis and characterization has become the first customer subscribing to its AurWEB portal.
AurWEB allows
researchers to gain access to all of Aureus' knowledge databases,
which include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug
interactions and hERG as well as the accompanying applications. All
are available via a highly secure web portal on a subscription
basis.
Origenis employs reliable, up-to-date knowledge bases to incorporate relevant biological and pharmacological data into the drug design process. Origenis uses proprietary methods to generate predictive QSAR and QSPR models for its evolutionary design, and creates pre-clinical compounds target and indication optimised using a direct multi-objective approach. "With AurWEB the data integration into MOREsystem® was straightforward" said Dr. Michael Thormann, Managing Director of Origenis GmbH. "AurWeb represents a valuable, exemplary data source. We use AurWeb to turn highly relevant knowledge into powerful models for our technology platform. This accelerates our drug discovery projects and improves the quality of the resulting compounds."
"We are pleased to have Origenis join our growing list of customers," said Dr. André Michel, CEO of Aureus Pharma. "AurWEB with its flexible access to biological and chemical activity data for important drug target families will complement Origenis approach to discover novel target focussed drug candidates."
Origenis employs reliable, up-to-date knowledge bases to incorporate relevant biological and pharmacological data into the drug design process. Origenis uses proprietary methods to generate predictive QSAR and QSPR models for its evolutionary design, and creates pre-clinical compounds target and indication optimised using a direct multi-objective approach. "With AurWEB the data integration into MOREsystem® was straightforward" said Dr. Michael Thormann, Managing Director of Origenis GmbH. "AurWeb represents a valuable, exemplary data source. We use AurWeb to turn highly relevant knowledge into powerful models for our technology platform. This accelerates our drug discovery projects and improves the quality of the resulting compounds."
"We are pleased to have Origenis join our growing list of customers," said Dr. André Michel, CEO of Aureus Pharma. "AurWEB with its flexible access to biological and chemical activity data for important drug target families will complement Origenis approach to discover novel target focussed drug candidates."